ATE384521T1 - Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen - Google Patents
Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungenInfo
- Publication number
- ATE384521T1 ATE384521T1 AT01924057T AT01924057T ATE384521T1 AT E384521 T1 ATE384521 T1 AT E384521T1 AT 01924057 T AT01924057 T AT 01924057T AT 01924057 T AT01924057 T AT 01924057T AT E384521 T1 ATE384521 T1 AT E384521T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- parasitic protozoa
- disease
- trypanosomiasis
- medicine
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000003071 parasitic effect Effects 0.000 title abstract 3
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical group OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 abstract 2
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 abstract 2
- 208000000230 African Trypanosomiasis Diseases 0.000 abstract 2
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 2
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 2
- 208000029080 human African trypanosomiasis Diseases 0.000 abstract 2
- 201000002612 sleeping sickness Diseases 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
- 108010018956 CTP synthetase Proteins 0.000 abstract 1
- 208000024699 Chagas disease Diseases 0.000 abstract 1
- 208000004554 Leishmaniasis Diseases 0.000 abstract 1
- 241000223105 Trypanosoma brucei Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000002311 trypanosomiasis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001531A SE0001531D0 (sv) | 2000-04-27 | 2000-04-27 | Medicament for the treatment of diseases caused by parasiticprotozoa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384521T1 true ATE384521T1 (de) | 2008-02-15 |
Family
ID=20279443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01924057T ATE384521T1 (de) | 2000-04-27 | 2001-04-20 | Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7157449B2 (de) |
| EP (1) | EP1284725B1 (de) |
| AT (1) | ATE384521T1 (de) |
| AU (1) | AU2001250722A1 (de) |
| DE (1) | DE60132581T2 (de) |
| ES (1) | ES2298229T3 (de) |
| SE (1) | SE0001531D0 (de) |
| WO (1) | WO2001080809A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060276438A1 (en) * | 2004-10-04 | 2006-12-07 | Natarajan Sethuraman | Prevention and treatment of influenza with glutamine antagonist agents |
| WO2014186435A2 (en) * | 2013-05-14 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for reducing neointima formation |
| WO2016201307A1 (en) * | 2015-06-12 | 2016-12-15 | The United State of America, as represented by the Secretary, Dept. of Health and Human Services | Glutamine antagonists for use in treating cerebral edema and cerebral malaria |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0445239A4 (en) * | 1989-06-21 | 1992-03-25 | The Catholic University Of America | Anti-malarial composition and method of use |
| US5180714A (en) * | 1990-10-31 | 1993-01-19 | Health Research, Inc. | Adenosine compounds for the treatment of diseases caused by parasitic protozoa |
| US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| US6025335A (en) * | 1995-09-21 | 2000-02-15 | Lipitek International, Inc. | L-Nucleoside Dimer Compounds and therapeutic uses |
| WO1998031375A1 (en) * | 1997-01-21 | 1998-07-23 | The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Sevices | Enhanced suppression of hiv-1 by the combination of cytidine nucleoside analogues and ctp synthase inhibitors |
-
2000
- 2000-04-27 SE SE0001531A patent/SE0001531D0/xx unknown
-
2001
- 2001-04-20 US US10/258,810 patent/US7157449B2/en not_active Expired - Fee Related
- 2001-04-20 WO PCT/SE2001/000864 patent/WO2001080809A2/en active IP Right Grant
- 2001-04-20 DE DE60132581T patent/DE60132581T2/de not_active Expired - Lifetime
- 2001-04-20 ES ES01924057T patent/ES2298229T3/es not_active Expired - Lifetime
- 2001-04-20 AU AU2001250722A patent/AU2001250722A1/en not_active Abandoned
- 2001-04-20 AT AT01924057T patent/ATE384521T1/de not_active IP Right Cessation
- 2001-04-20 EP EP01924057A patent/EP1284725B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7157449B2 (en) | 2007-01-02 |
| EP1284725B1 (de) | 2008-01-23 |
| EP1284725A2 (de) | 2003-02-26 |
| DE60132581T2 (de) | 2009-01-29 |
| WO2001080809A3 (en) | 2002-02-28 |
| SE0001531D0 (sv) | 2000-04-27 |
| AU2001250722A1 (en) | 2001-11-07 |
| US20030109505A1 (en) | 2003-06-12 |
| DE60132581D1 (de) | 2008-03-13 |
| ES2298229T3 (es) | 2008-05-16 |
| WO2001080809A2 (en) | 2001-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1885333T3 (da) | Farmaceutisk formulering af apomorphin til bukkal indgivelse | |
| DE602004028841D1 (de) | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c | |
| ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
| EP1562897A4 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| DK0853083T3 (da) | Pyridylfuran- og piridylthiophenforbindelser og farmaceutisk anvendelse deraf | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| SE0104340D0 (sv) | New compounds | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| PT1404347E (pt) | Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c | |
| DE60236541D1 (de) | Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
| BRPI0509074A (pt) | composições farmacêuticas compreendendo agonistas do receptor da tiróide | |
| HUP0303082A2 (hu) | Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| HUP0203844A2 (hu) | Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása | |
| HUP0204520A2 (en) | Pharmaceutical composition containing esmolol and process for its preparation | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
| EA200700979A1 (ru) | Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола | |
| MA27474A1 (fr) | Vaccin | |
| ATE384521T1 (de) | Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen | |
| ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis | |
| RS60604A (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
| HUP0402062A2 (hu) | Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények | |
| DE60319254D1 (de) | Pyrazolamide zur behandlung von hiv-infektionen | |
| HUP0401940A2 (hu) | Diabetikus neuropátia esetében alkalmazható gyógyszerkészítmény |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |